These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32963061)

  • 1. Prevalence and factors associated with false hyperkalaemia in Asians in primary care: a cross-sectional study (the Unlysed Hyperkalaemia- the Unseen Burden (UHUB) study).
    Boo AYY; Koh YLE; Hu PL; Tan NC
    BMJ Open; 2020 Sep; 10(9):e033755. PubMed ID: 32963061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
    Raml A; Schmekal B; Grafinger P; Biesenbach G
    Dtsch Med Wochenschr; 2001 Nov; 126(47):1327-30. PubMed ID: 11719857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of differences between point-of-care blood gas analyser and laboratory analyser potassium results on hyperkalaemia diagnosis & treatment.
    Pradhan J; Harding AM; Taylor SE; Lam Q
    Intern Med J; 2023 Nov; 53(11):2035-2041. PubMed ID: 36645311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A determination of the current causes of hyperkalaemia and whether they have changed over the past 25 years.
    Muschart X; Boulouffe C; Jamart J; Nougon G; Gérard V; de Cannière L; Vanpee D
    Acta Clin Belg; 2014 Aug; 69(4):280-4. PubMed ID: 24942977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients.
    Indermitte J; Burkolter S; Drewe J; Krähenbühl S; Hersberger KE
    Drug Saf; 2007; 30(1):71-80. PubMed ID: 17194172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperkalaemia prevalence and dialysis patterns in Chinese patients on haemodialysis: an interim analysis of a prospective cohort study (PRECEDE-K).
    Ni Z; Jin H; Lu R; Zhang L; Yao L; Shao G; Zuo L; Qin S; Zhang X; Zhang Q; Yu W; Luo Q; Ren Y; Peng H; Xiao J; Yang Q; Chen Q; Shi Y;
    BMC Nephrol; 2023 Aug; 24(1):233. PubMed ID: 37559023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure.
    Maggioni AP; Dondi L; Andreotti F; Calabria S; Iacoviello M; Gorini M; Gonzini L; Piccinni C; Ronconi G; Martini N
    Eur J Clin Invest; 2021 Aug; 51(8):e13551. PubMed ID: 33786826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.
    Sarafidis PA; Blacklock R; Wood E; Rumjon A; Simmonds S; Fletcher-Rogers J; Ariyanayagam R; Al-Yassin A; Sharpe C; Vinen K
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1234-41. PubMed ID: 22595825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the risk of hyperkalaemia and acute kidney injury with cotrimoxazole: a retrospective observational study.
    Rajput J; Moore LSP; Mughal N; Hughes S
    Clin Microbiol Infect; 2020 Dec; 26(12):1651-1657. PubMed ID: 32220637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK.
    Linde C; Qin L; Bakhai A; Furuland H; Evans M; Ayoubkhani D; Palaka E; Bennett H; McEwan P
    ESC Heart Fail; 2019 Apr; 6(2):280-290. PubMed ID: 30629342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population-based cohort study.
    Thomsen RW; Nicolaisen SK; Adelborg K; Svensson E; Hasvold P; Palaka E; Pedersen L; Sørensen HT
    Diabet Med; 2018 Aug; 35(8):1051-1060. PubMed ID: 29790603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey.
    Rossignol P; Lamiral Z; Frimat L; Girerd N; Duarte K; Ferreira J; Chanliau J; Castin N
    Nephrol Dial Transplant; 2017 Dec; 32(12):2112-2118. PubMed ID: 28460113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin II receptor blockers on serum potassium level and hyperkalemia risk: retrospective single-centre analysis.
    Fukushima S; Oishi M; Aso H; Arai K; Sasaki Y; Tochikura N; Ootsuka S; Fukuoka N; Ooba N; Kikuchi N
    Eur J Hosp Pharm; 2023 Jul; 30(4):208-213. PubMed ID: 34183459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperkalaemia in the emergency department: Epidemiology, management and monitoring of treatment outcomes.
    Pollack K; Manning KR; Balassone J; Bui C; Taylor DM; Taylor SE
    Emerg Med Australas; 2022 Oct; 34(5):751-757. PubMed ID: 35411698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum potassium abnormalities in chronic kidney disease: prevalence, patient characteristics and clinical outcomes.
    Brookes EM; Snider J; Hart GK; Robbins R; Power DA
    Intern Med J; 2021 Nov; 51(11):1906-1918. PubMed ID: 33314585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease.
    Nakhoul GN; Huang H; Arrigain S; Jolly SE; Schold JD; Nally JV; Navaneethan SD
    Am J Nephrol; 2015; 41(6):456-63. PubMed ID: 26228532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperkalaemia in diabetes: prevalence and associations.
    Jarman PR; Kehely AM; Mather HM
    Postgrad Med J; 1995 Sep; 71(839):551-2. PubMed ID: 7479468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.